Our flagship biopharmaceutical product is semaglutide (R&D use). Semaglutide is a GLP-1 receptor agonist widely used for the treatment of type 2 diabetes and obesity. Leveraging our proprietary recombinant expression and enzymatic peptide assembly technologies, we manufacture semaglutide (R&D use) with a purity of 98% or higher, while significantly reducing production costs compared to traditional chemical synthesis routes. Furthermore, we supply an extensive range of peptide fragments, protected amino acids, and other specialized intermediates dedicated to peptide drug synthesis.